## Investigation of Choice for ASCUS Management **Key Point:** HPV DNA testing (specifically high-risk types 16 and 18) is the gold standard reflex test for ASCUS cytology to stratify risk and guide colposcopy referral. ### Rationale for HPV DNA Testing 1. **Risk Stratification** - HPV-positive ASCUS → 25–30% risk of CIN2+ → colposcopy indicated - HPV-negative ASCUS → <5% risk of CIN2+ → routine screening sufficient 2. **High-Yield Clinical Pearl:** The 2019 ASCCP guidelines recommend HPV DNA testing as the preferred reflex test for ASCUS. PCR-based detection of high-risk HPV (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) is most sensitive and specific. 3. **Advantages Over Other Tests** - More sensitive than repeat cytology - Identifies persistent infection (key driver of malignancy) - Reduces unnecessary colposcopies in HPV-negative women ### Comparison of Approaches | Investigation | Sensitivity | Specificity | Use Case | |---|---|---|---| | HPV DNA PCR | 95–99% | 90–95% | Reflex test for ASCUS (guideline-standard) | | Repeat Pap smear | 60–80% | 95% | Delayed, lower sensitivity; not preferred | | Colposcopy immediate | 90% | 60% | Overtreatment of low-risk ASCUS | | HPV serology | 70% | 60% | Past/chronic infection; poor for acute risk | **Warning:** Serology (antibodies) reflects past or chronic infection and does NOT predict current risk of malignancy — it is not used for triage of cytologic abnormalities.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.